Feasibility of gadolinium contrast use in transcatheter aortic valve implantation: a non-iodine-based procedure—case report

Iodine-based contrast agents can be associated to uncommon side effects, as the generalized bullous fixed drug eruption (gbFDE), that cannot be counteracted by drugs.

We report a case of TAVI performed with a gadolinium-based contrast agent in a patient that had previously experienced a severe form of gbFDE. The patient was successfully treated by a balloon-expandable prosthesis implanted under the guidance of a total of 30 cc of gadolinium injections, avoiding any side effect.

Thus, the planning of TAVI procedure with zero iodinated contrast is mandatory in high-risk patients for such complication and it is feasible, safe with a gadolinium-based contrast.